Emcure Pharmaceuticals receives Income-tax penalty orders aggregating Rs. 57,73,96,732
Emcure Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Penalty imposed for Financial Year 2014-15 to Financial Year 2020-21 (Assessment Year 2015-16 to Assessment Year 2021-22)
- Aggregate penalty amount is Rs. 57,73,96,732
- Company is evaluating appropriate legal remedies, including filing an appeal before the Appellate Authority
Why it's rated notable: Income-tax orders impose an aggregate penalty of Rs. 57,73,96,732, about 0.6% of the ₹9,683 crore annual revenue, and the company is still evaluating an appeal, so the filing is an adverse order of moderate size rather than a large penalty.
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Engineering Services
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Emcure Pharmaceuticals
- Acquisition / mergerNotableEmcure Pharmaceuticals acquires full ownership of Gennova Biopharmaceuticals
Other other filings this fortnight
- Star Health fined ₹2 crore by IRDAI for claim settlement issues in 2022 inspection
- Star Health fined ₹2 crore by IRDAI for claim settlement issues
- Protean eGov Technologies receives upheld GST penalty order dated Nov 17, 2026
- OtherSML MahindraMahindra & Mahindra Limited files Rights Issue Letter of Offer dated Nov 16, 2026
- OtherEasy Trip PlannersEasy Trip Planners Limited releases Q2 and H1 FY 2026 financial results and announces CMO resignation
- Salasar Techno Engineering Limited reports Q2 & H1 FY27 financial results and disclosures
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.
